White House, Trump and Novo Nordisk
Digest more
Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...
The White House has secured another deal with major pharmaceutical companies, this time to offer popular weight loss drugs ...
Eli Lilly and Novo Nordisk will lower prices for GLP-1 drugs, aligning with new drug pricing initiatives and Medicare Part D pilot coverage starting April 2026. Lilly's Zepbound and orforglipron will ...
The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.
A White House guest collapsed behind President Trump during an Oval Office press conference, leading to an abrupt pause in ...
Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...
The agreement will also secure a $150 price for future weight loss pills from Novo Nordisk and Eli Lilly—at least initially.
A pharmaceutical executive fainted Thursday at the White House during President Donald Trump's announcement on weight loss ...
The White House is expected to announce a deal for lower prices of obesity drugs from Novo Nordisk and Eli Lilly on Thursday ...
Ahead of a reported White House deal meant to lower the cost of obesity drugs like Wegovy, Novo said “intensifying ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback